Role of Efficacy Data in Selecting Optimal Therapy for Patients With Relapsed/Refractory CLL
Centering conversation on patients with relapsed/refractory chronic lymphocytic leukemia, Andrew Lipsky, MD, reviews efficacy data and considers how it impacts treatment selection.
Transcript:
Andrew H. Lipsky, MD: I think the progression-free survival is an incredibly meaningful end point for clinical trials in CLL [chronic lymphocytic leukemia]. To some extent, this reflects a consequence of our success in treating the disease. If you think about the median age of CLL patients, giving them more time on therapy with a limited number of side effects and good quality of life, that’s a really meaningful improvement in their overall ability to live with the disease. When it comes to overall survival benefits, those have been seen in comparisons of head-to-head trials of BTK [Bruton tyrosine kinase] inhibition to chemoimmunotherapy, and that demonstrates how far we’ve come in treating CLL. And that underlies the rationale for me that we really shouldn’t be giving chemoimmunotherapy anymore when treating this disease.
Transcript edited for clarity.
Lipsky Discusses Second-Generation BTK Inhibitors in Relapsed/Refractory CLL
October 12th 2024During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK inhibitors used to treat patients with chronic lymphocytic leukemia.
Read More
